Compare TCBK & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBK | NUVB |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | 1148 | 305 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 1995 | 2020 |
| Metric | TCBK | NUVB |
|---|---|---|
| Price | $53.11 | $6.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $54.60 | $11.38 |
| AVG Volume (30 Days) | 202.8K | ★ 4.2M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | 6.94 | ★ 71.56 |
| EPS | ★ 2.10 | N/A |
| Revenue | $53,445,000.00 | ★ $62,902,000.00 |
| Revenue This Year | $12.03 | $203.82 |
| Revenue Next Year | $4.47 | $58.18 |
| P/E Ratio | $25.52 | ★ N/A |
| Revenue Growth | 4.12 | ★ 698.96 |
| 52 Week Low | $40.44 | $3.00 |
| 52 Week High | $61.71 | $9.75 |
| Indicator | TCBK | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 43.77 |
| Support Level | $52.34 | $5.95 |
| Resistance Level | $55.00 | $6.25 |
| Average True Range (ATR) | 0.92 | 0.28 |
| MACD | 0.06 | -0.09 |
| Stochastic Oscillator | 30.73 | 27.33 |
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income. Its banking and financial services are provided through full-service branches and commercial banking offices across California.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.